Nkcfo LLC Takes Position in OraSure Technologies, Inc. (NASDAQ:OSUR)

Nkcfo LLC purchased a new stake in OraSure Technologies, Inc. (NASDAQ:OSUR) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 25,000 shares of the medical instruments supplier’s stock, valued at approximately $205,000.

A number of other large investors also recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in shares of OraSure Technologies by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 5,396,285 shares of the medical instruments supplier’s stock valued at $32,000,000 after purchasing an additional 64,367 shares during the period. Cannell Capital LLC lifted its stake in shares of OraSure Technologies by 36.5% in the 3rd quarter. Cannell Capital LLC now owns 2,820,591 shares of the medical instruments supplier’s stock valued at $16,726,000 after purchasing an additional 753,901 shares during the period. Pacer Advisors Inc. lifted its stake in shares of OraSure Technologies by 122.5% in the 4th quarter. Pacer Advisors Inc. now owns 2,403,333 shares of the medical instruments supplier’s stock valued at $19,707,000 after purchasing an additional 1,323,197 shares during the period. Invesco Ltd. lifted its stake in shares of OraSure Technologies by 4.9% in the 3rd quarter. Invesco Ltd. now owns 1,282,378 shares of the medical instruments supplier’s stock valued at $7,605,000 after purchasing an additional 59,801 shares during the period. Finally, AQR Capital Management LLC increased its position in shares of OraSure Technologies by 118.0% in the 3rd quarter. AQR Capital Management LLC now owns 935,510 shares of the medical instruments supplier’s stock valued at $5,548,000 after buying an additional 506,312 shares in the last quarter. Institutional investors and hedge funds own 93.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on OSUR shares. Evercore ISI lowered their price objective on shares of OraSure Technologies from $7.00 to $6.50 and set an “in-line” rating for the company in a research report on Thursday, April 4th. StockNews.com upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating in a research report on Wednesday. Two investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $6.38.

OraSure Technologies Price Performance

OSUR stock traded up $0.01 during trading hours on Friday, reaching $5.49. 668,077 shares of the stock were exchanged, compared to its average volume of 687,993. The firm’s 50-day moving average is $6.18 and its 200-day moving average is $6.81. The company has a market cap of $420.04 million, a price-to-earnings ratio of 7.63 and a beta of 0.23. OraSure Technologies, Inc. has a 12 month low of $4.38 and a 12 month high of $8.45.

OraSure Technologies (NASDAQ:OSUR) last released its earnings results on Tuesday, February 27th. The medical instruments supplier reported $0.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.09. The firm had revenue of $75.88 million during the quarter, compared to analysts’ expectations of $74.13 million. OraSure Technologies had a return on equity of 14.50% and a net margin of 13.23%. The company’s revenue was down 38.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.21 EPS. As a group, equities research analysts forecast that OraSure Technologies, Inc. will post -0.11 earnings per share for the current year.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.